Micronized Glyburide Tablets Articles
Upjohn "Violated State Business Practice Laws"
8 August 1994
UPJOHN APPROVAL
13 December 1993
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
RISK YEARS AHEAD FOR UPJOHNFOR UPJOHN
22 March 1993
Hoechst Roussel has no plans to market Glubate
22 June 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
Showing 1-7 of 7 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
